[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diagnostics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diagnostics":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100515307","rapid-research-in-diagnostics-development-for-tb-network-r2d2-kids-and-assessing-diagnostics-at-poc-for-tb-in-children-adapt-for-kids-100515307",false,"NCT05989802","Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and Assessing Diagnostics At POC for TB in Children (ADAPT for Kids)","Rapid Research in Diagnostics Development for Tuberculosis Network (R2D2 Kids) and Assessing Diagnostics At Point-of-care for Tuberculosis in Children (ADAPT for Kids)","Participant eligibility criteria:\n\nParticipants will include children (age \\\u003C15 years) who present to care with:\n\nA. 2 or more of the following:\n\n* Unexplained cough for any duration\n* TB contact or tuberculin skin test or interferon gamma release assay positive\n* Abnormal chest X-ray (any abnormality) OR\n\nB. Any one of criteria A AND any one of the following:\n\n* Unexplained weight loss OR unexplained failure to thrive OR Severe Acute Malnutrition\n* Unexplained fever ≥2 weeks\n* Unexplained lethargy or reduced playfulness ≥2 weeks\n\nThe study will exclude participants who:\n\n1. Completed preventive or active TB treatment within the past 12 months (to increase TB prevalence and reduce false-positive results, respectively);\n2. Have taken any medication with anti-mycobacterial activity for any reason for greater than 3 days at the time of enrollment (to reduce false-negatives);\n3. Are unable to return for follow-up visits; or\n4. Whose parents\u002Fguardians are unwilling to provide informed consent or who are unwilling to provide assent if applicable (age determined by local IRB)\n\nAssessment of the usability of novel TB tests:\n\nThe study will also include health workers at each clinical site who are 1) aged ≥18 years and 2) involved in routine TB testing (collecting specimens for or performing TB tests). Personnel who are unwilling to provide informed consent will be excluded.",true,"ALL","65 Years",{"count":20,"type":21},2100,"ESTIMATED","INTERVENTIONAL",[24],"NA","Every year there are an estimated 230,000 childhood deaths from TB. There is an urgent need for novel tests for TB diagnosis in children under 15 years. The Rapid Research in Diagnostics Development for TB Network (R2D2 Kids) and the Assessing Diagnostics at Point-of-care for Tuberculosis in children (ADAPT for Kids) studies seek to reduce the burden of TB worldwide by evaluating faster, simpler, and less expensive TB triage and diagnostic tests for use in children.",[27,28,29],"Tuberculosis","Diagnostics","Global Health","RECRUITING","2026-03-09",{"date":33,"type":34},"2026-03-11","ACTUAL",{"date":36,"type":34},"2024-01-26",{"date":38,"type":21},"2026-09-01",{"name":40,"class":41},"University of California, San Francisco","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100600523","phase-2-pancreatic-cancer-diagnosis-with-fapi-pet-imaging-100600523","NCT07098598","Pancreatic Cancer Diagnosis With FAPI-PET Imaging","Diagnostic Efficacy of 18F-FAPI-74 PET\u002FCT in Patients With Pancreatic Cancer","Inclusion Criteria:\n\n* Suspected primary or recurrent pancreatic cancer\n* Subjects must be male or female aged 18-85 years.\n* WHO performance score 0-2.\n* Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.\n\nExclusion Criteria:\n\n* Vulnerable study subjects such as described in Finnish law clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included.\n* Study subject is not able to understand the purpose of the study.\n* Medical conditions prohibiting whole-body PET\u002FCT imaging.","18 Years","85 Years",{"count":52,"type":21},100,[54,55],"PHASE2","PHASE3","Staging pancreatic cancer (PC) presents a clinical challenge. Triphasic whole body CT is the primary imaging method in diagnosing, staging and during follow up. Conventional PET\u002FCT with 18F-labelled fluorodeoxyglucose (18F-FDG) has its limitations and therefore has a secondary role in imaging pancreatic cancer patients. These conventional imaging methods are good in detecting primary tumors and distant metastasis but poor in detecting local lymph node metastasis. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targets FAP, a protein overexpressed in cancer-associated fibroblasts. It presents a potential new PET imagining tool.\n\nThe objective of this prospective diagnostic study is to evaluate the diagnostic efficacy of 18F-FAPI-74 PET\u002FCT in patients with PC. The aim is to evaluate the sensitivity and specificity of 18F-FAPI-74 in detection of local lymph node metastasis and distant metastasis in patient level in patients with PC in primary staging and when suspected recurrence. 100 patients with PC are enrolled on whom PET\u002FCT studies are performed with the novel 18F-FAPI-74 tracer. The data will be collected between 2024-2026.",[58,59,60,28,61,62,63,64],"Positron Emission Tomography","Pancreatic Cancer","FAPI","Recurrent Pancreatic Cancer","Oncologic Surgery","Imaging, Diagnostic","Staging","2025-07-31",{"date":67,"type":34},"2025-08-01",{"date":69,"type":34},"2024-10-09",{"date":71,"type":21},"2026-10",{"name":73,"class":74},"Turku University Hospital","OTHER_GOV",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":16,"sex":17,"minAge":84,"maxAge":18,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100588296","high-throughput-serological-testing-of-antibodies-platform-100588296","NCT06939556","High-throughput Serological Testing of Antibodies Platform","Development of a High-throughput Serological Testing Platform for Mass Screening Purposes of Both Pediatric and Adult Cohorts","DEVHISE","Inclusion Criteria:\n\nAdult Cohort - between 20 and 65 years of age Pediatric Cohort - between 2 and 10 years of age Signed consent form by the subject for adults or by caregivers for children\n\nExclusion Criteria:\n\n1. subjects with an immunocompromised status, such as immunodeficiency disorders or those undergoing immunosuppressant treatments\n2. subjects with underlying chronic inflammatory conditions (i.e., autoimmune disorders, chronic gastrointestinal, and rheumatic conditions)\n3. subjects who have received immunomodulatory treatment within the past year.","2 Years",{"count":86,"type":21},152,"OBSERVATIONAL","In the case of large emergency serosurveys, innovation in the sampling techniques is an often neglected, but relevant aspect to facilitate the enrolment of subjects in both adult and paediatric populations. Further, neutralization assays are the first line of response immediately after the emergence of a novel virus in the human population. This study aims at developing at IZSVe 384-format high-throughput neutralization assays for emerging and re-emerging respiratory viruses with pandemic potential to increase the preparedness capacity at both regional and national levels. This diagnostic platform will include the validation of Mitra VAMS devices for gathering blood samples for the diagnostic procedure. The platform will be tested and validated using adult subject-matched serum samples collected by venipuncture and finger-prick with volumetric tip microsampling devices (Mitra VAMS). This comparison will focus on the titration of antibodies against endemic viruses like influenza type A (i.e., seasonal influenza strains, like pdmH1N1 or H3N2) and SARS-CoV-2. The same serological assay will be developed to titrate neutralizing antibodies against emerging pathogens like avian influenza viruses of the H3 and H5 subtypes, Zika virus, and MERS-CoV.",[28,90],"Pandemic Response",[92,93,94,95],"pandemic preparedness","serology","high-throughput","emergent infectious diseases","2025-06-04",{"date":98,"type":34},"2025-06-08",{"date":100,"type":34},"2025-04-15",{"date":102,"type":21},"2025-10-31",{"name":104,"class":41},"Istituto Zooprofilattico Sperimentale delle Venezie",2]